Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
52.1(c) 52.65(c) 52.75(c) 54.3(c) 54.35(c) Last
353 078 249 155 171 099 455 657 278 865 Volume
-0.76% +1.06% +0.19% +2.94% +0.09% Change
More quotes
Financials ($)
Sales 2017 536 M
EBIT 2017 140 M
Net income 2017 95,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 583 M
EBIT 2018 154 M
Net income 2018 103 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 19,20
P/E ratio 2018 17,70
Capi. / Sales2017 3,28x
Capi. / Sales2018 3,01x
Capitalization 1 758 M
More Financials
Company
Cambrex Corp. engages in the provisio ofproducts, services and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies its products and services to innovator and generic pharmaceutical companies.Its products include generic and... 
Sector
Pharmaceuticals
Calendar
02/22 | 02:00pmPresentation
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
02/15 Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conferen..
02/08 CAMBREX : riding high on demand for Western innovator APIs
02/03 CAMBREX CORPORATION : (CBM) Jumps on Earnings Estimate
02/03 CAMBREX : Management's Discussion and Analysis of Financial Condition and Result..
02/03 CAMBREX : posts 4Q profit
02/03 CAMBREX CORPORATION (NYSE : CBM) Files An 8-K Results of Operations and Financia..
02/03 CAMBREX CORP : Results of Operations and Financial Condition, Financial Statemen..
02/03 Cambrex Reports Fourth Quarter and Full Year 2016 Financial Results
02/01 Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on Fe..
01/05 CAMBREX : Talks continue on site for North Haven train station
More news
Sector news : Pharmaceuticals - NEC
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
02/17Cambrex Corporation upgraded by Zacks Investment Research to hold.  
02/15Steven M. Klosk Sells 63,178 Shares of Cambrex Corporation $CBM Stock  
02/09Craig Hallum Analysts Give Cambrex Corporation $CBM a $70.00 Price Target  
02/09Cambrex Corporation downgraded by Zacks Investment Research to sell.  
02/07Cambrex Corporation $CBM Given a $70.00 Price Target by Craig Hallum Analysts.. 
More tweets
Qtime:13
News from SeekingAlpha
02/15 CAMBREX : A Pure Growth Play
02/03 Cambrex's (CBM) CEO Steven Klosk on Q4 2016 Results - Earnings Call Transcrip..
02/03 Midday Gainers / Losers
02/03 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 am
02/03 Cambrex revenues up 14%; non-GAAP EPS up 22% in Q4; updates guidance
Advertisement
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Full-screen chart
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 56,8 $
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION0.74%1 758
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results